This comprehensive guide provides an overview of the coding, coverage and payment landscape for the WATCHMAN system.

For questions regarding WATCHMAN™ reimbursement, please contact:

Email: WATCHMAN.Reimbursement@bsci.com

Phone (toll free): (877) 786-1050

Please go to www.watchmandownloadcenter.com for additional resources.
INDICATIONS FOR USE
WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

• Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy;
• Are deemed by their physicians to be suitable for warfarin; and
• Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin, taking into account the safety and effectiveness of the device compared to warfarin.

CONTRAINDICATIONS
Do not use the WATCHMAN Device if:

• Intracardiac thrombus is present.
• An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
• The LAA anatomy will not accommodate a device. See Table 47 (in the DFU).
• Intracardiac thrombus is present.
• Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
• There are contraindications to the use of warfarin, aspirin, or clopidogrel.
• The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section) such that the use of the WATCHMAN device is contraindicated.

WARNINGS
• Device selection should be based on accurate LAA measurements obtained using echocardiographic imaging guidance (TEE recommended) in multiple angles (e.g., 0º, 45º, 90º, 135º).
• Do not release the WATCHMAN Device from the core wire if the device does not meet all release criteria.
• If thrombus is observed on the device, warfarin therapy is recommended until resolution of thrombus is demonstrated by TEE.
• The potential for device embolization exists with cardioversion <30 days following device implantation. Verify device position post-cardioversion during this period.
• Administer appropriate endocarditis prophylaxis for 6 months following device implantation. The decision to continue endocarditis prophylaxis beyond 6 months is at physician discretion.
• For single use only. Do not reuse, reprocess or resterilize.

PRECAUTIONS
• The safety and effectiveness (and benefit-risk profile) of the WATCHMAN Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
• The LAA is a thin-walled structure. Use caution when accessing the LAA and deploying the device.
• Use caution when introducing the WATCHMAN Access System to prevent damage to cardiac structures.
• Use caution when introducing the Delivery System to prevent damage to cardiac structures.
• To prevent damage to the Delivery Catheter or device, do not allow the WATCHMAN Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
• If using a power injector, the maximum pressure should not exceed 100 psi.
• In view of the concerns that were raised by the RE-ALIGN study of dabigatran in the presence of prosthetic mechanical heart valves, caution should be used when prescribing oral anticoagulants other than warfarin in patients treated with the WATCHMAN Device. The WATCHMAN Device has only been evaluated with the use of warfarin post-device implantation.

ADVERSE EVENTS
Potential adverse events (in alphabetical order) which may be associated with the use of the WATCHMAN Implant or implantation procedure include but are not limited to: air embolism, airway trauma, allergic reaction to contrast media, anesthetic, WATCHMAN Implant material, or medications, altered mental status, anemia requiring transfusion, anemia risk, angina, anoxic encephalopathy, arrhythmias, atrial septal defect, bruising, hematomata or seroma near the catheter insertion site, cardiac perforation, chest pain/discomfort, confusion post procedure, congestive heart failure, contrast related nephropathy, cranial bleed, death, decreased hemoglobin, deep vein thrombosis, device embolism, device fracture, device thrombosis, edema, embolism, excessive bleeding, fever, fistula, groin pain, groin puncture bleed, hematuria, hemoptysis, hypotension, hypoxia, improper wound healing, inability to reposition, recapture, or retrieve the device, infection/pneumonia, interatrial septum thrombus, intratracheal bleeding, major bleeding requiring transfusion, myocardial erosion, nausea, oral bleeding, pericardial effusion/tamponade, pleural effusion, prolonged bleeding from a laceration, pseudoaneurysm, pulmonary edema, renal failure, respiratory insufficiency/failure, surgical removal of the device, stroke – hemorrhagic, stroke – ischemic, systemic embolism, TEE complications (throat pain, bleeding, esophageal trauma), thrombocytopenia, thrombosis, transient ischemic attack (TIA), valvular or vascular damage, vasovagal reactions.

There may be other potential adverse events that are unforeseen at this time.

TABLE OF CONTENTS

WATCHMAN Left Atrial Appendage Closure Device
2020 Reimbursement Guide

Coding Summary.................................................................................................................................3
ICD-10-CM Diagnosis Codes...........................................................................................................4
Hospital Reimbursement ..............................................................................................................5-7
Physician Reimbursement ...........................................................................................................8-11
Professional Claim Billing Instructions.......................................................................................12-13
Institutional Hospital Claims Billing Instructions........................................................................14-16
Discontinued or Aborted Procedure for Inpatient Services.....................................................17-18
Concomitant Procedure Billing.................................................................................................19-20
National Coverage Determination (NCD) ..................................................................................21-23
Medicare Advantage, Medicaid and Commercial Insurance....................................................24-27
Additional Resources – Health Economics and Market Access Webinars.........................28
Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services.

It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered.

Boston Scientific recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label.

CPT Copyright 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements. The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options.
## CODING SUMMARY

<table>
<thead>
<tr>
<th>Coding</th>
<th>Hospital Inpatient</th>
<th>Physician</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10-PCS Procedure Code</td>
<td><strong>02L73DK</strong></td>
<td>CPT Code <strong>33340</strong></td>
</tr>
<tr>
<td>Payment</td>
<td><strong>MS-DRG 273</strong> or <strong>MS-DRG 274</strong></td>
<td>14 Work RVUs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.93 Total RVUs</td>
</tr>
</tbody>
</table>

### Diagnosis Codes
- **ICD-10-CM Diagnosis Codes**
  - **I48.91** Unspecified Atrial Fibrillation
  - **I48.20** Chronic Atrial Fibrillation, Unspecified*
  - **I48.21** Permanent Atrial Fibrillation
  - **I48.0** Paroxysmal Atrial Fibrillation
  - **I48.11** Longstanding Persistent Atrial Fibrillation
  - **I48.19** Other Persistent Atrial Fibrillation

### Coverage
- **Original Medicare** – CMS National Coverage Determination (NCD CED 20.34) establishes uniform coverage criteria¹
- **Medicare Advantage** – Medicare Advantage plans must cover all the services that Original Medicare covers. The NCD CED 20.34 coverage criteria for Original Medicare also provides coverage to Medicare Advantage Patients²
- **Private Payers** – Coverage dependent on individual payer policy

*The unspecified code is **NOT COVERED** under the NCD for LAAC. LAAC claims reported with this diagnosis code will be denied. Some private payers have included this ICD-10-CM code in their coverage policy.


ICD-10-CM DIAGNOSIS CODES

FY 2020 ICD-10-CM Atrial Fibrillation Diagnosis Coding Update

Updates to ICD-10-CM diagnosis codes related to Atrial Fibrillation were announced in the FY 2020 IPPS Final Rule and are effective as of October 1, 2019. Updates are described in CMS 2382, change request #11491.

Use of the new codes is required to facilitate claims processing for services associated with an AF diagnosis, including Left Atrial Appendage Closure (LAAC).

<table>
<thead>
<tr>
<th>Previous Code(s) Assignment</th>
<th>Current Code Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>End Date September 30, 2019</td>
<td>FY 2020 – Effective October 1, 2019</td>
</tr>
<tr>
<td>I48.91 Unspecified Atrial Fibrillation</td>
<td>I48.91 Unspecified Atrial Fibrillation</td>
</tr>
<tr>
<td>I48.2 Chronic Atrial Fibrillation</td>
<td>I48.20 Chronic Atrial Fibrillation, Unspecified*</td>
</tr>
<tr>
<td>I48.0 Paroxysmal Atrial Fibrillation</td>
<td>I48.21 Permanent Atrial Fibrillation</td>
</tr>
<tr>
<td>I48.1 Persistent Atrial Fibrillation</td>
<td>I48.0 Paroxysmal Atrial Fibrillation</td>
</tr>
<tr>
<td></td>
<td>I48.11 Longstanding Persistent Atrial Fibrillation</td>
</tr>
<tr>
<td></td>
<td>I48.19 Other Persistent Atrial Fibrillation</td>
</tr>
</tbody>
</table>

*The unspecified code is NOT COVERED under the NCD for LAAC. LAAC claims reported with this diagnosis code will be denied.
Medicare classifies WATCHMAN LAAC procedures as Inpatient-only.

The “Two-Midnight Rule” is not applicable for procedures restricted to the Inpatient Only (IPO) list.

<table>
<thead>
<tr>
<th>ICD-10-PCS</th>
<th>MS-DRG Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02L73DK</td>
<td>Occlusion of left atrial appendage with intraluminal device, percutaneous approach.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS-DRG</th>
<th>MS-DRG Description</th>
<th>FY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DRG 273</td>
<td>Percutaneous Intracardiac Procedures with MCC</td>
<td>$23,240</td>
</tr>
<tr>
<td>MS-DRG 274</td>
<td>Percutaneous Intracardiac Procedures without MCC</td>
<td>$19,792</td>
</tr>
</tbody>
</table>


**Major Complication or Comorbidity (MCC) Examples**

- End Stage Renal Disease (N18.6)
- Acute Respiratory Failure (J96.00, J96.01, J95.821)
- Acute on Chronic Heart Failure (I50.23, I50.33, I50.43)
- Acute Diastolic Heart Failure (I50.31)
**Transesophageal Echocardiogram (TEE) — Baseline and Follow-Up**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>APC</th>
<th>CY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>93312</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report.</td>
<td>5524</td>
<td>$482</td>
</tr>
</tbody>
</table>

*Commercial payment will vary and will be at discretion of the payer.

**Computed Tomography (CT) — Baseline and Follow-Up**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>APC</th>
<th>CY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>75572</td>
<td>Computed tomography, heart, with contrast structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed).</td>
<td>5571</td>
<td>$182</td>
</tr>
<tr>
<td>75574</td>
<td>Computed tomography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Commercial payment will vary and will be at discretion of the payer.*
**Transesophageal Echocardiogram (TEE) — Intraoperative**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>APC</th>
<th>CY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>93355</td>
<td>Echocardiography, transesophageal (TEE) for guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (e.g., TAVR, transcatheter pulmonary valve replacement, mitral valve repair, paravalvular regurgitation repair, left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural), real-time image acquisition and documentation, guidance with quantitative measurements, probe manipulation, interpretation, and report, including diagnostic transesophageal echocardiography and, when performed, administration of ultrasound contrast, Doppler, color flow, and 3D.</td>
<td>Not Applicable – N Status Indicator</td>
<td>Bundled Service</td>
</tr>
</tbody>
</table>

*Commercial payment will vary and will be at discretion of the payer.
## WATCHMAN LAAC Procedure

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>RVU</th>
<th>CY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>33340</td>
<td>Percutaneous transcatheter closure of the left atrial appendage with implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, radiological supervision and interpretation.</td>
<td>14.00 work RVUs, 22.93 Total RVUs</td>
<td>$829</td>
</tr>
</tbody>
</table>

*Commercial payment will vary and will be at discretion of the payer.

### Same Physician Performing Implant and Intraoperative TEE

CPT 33340 (WATCHMAN) and 93355 (Intraoperative TEE) cannot be billed by the physician billing 33340.

Continued

Co-Surgeon Billing

<table>
<thead>
<tr>
<th>CPT Code + Modifier</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>33340-62</td>
<td>Left atrial appendage closure can be billed by two surgeons by appending the -62 modifier to 33340 (eg. 33340-62).</td>
</tr>
</tbody>
</table>

- If two surgeons (each of a different specialty) are required to perform a specific procedure, each surgeon bills for the procedure with a modifier of “-62”
- Each operator is required to submit their own post-operative note and must report 33340-62
- The fee schedule amount applicable to the payment for each co-surgeon is 62.5 percent of the global surgery fee amount

Transesophageal Echocardiogram (TEE) — Baseline and Follow-Up

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>RVU</th>
<th>CY 2020 National Average Payment**</th>
</tr>
</thead>
<tbody>
<tr>
<td>93312</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report.</td>
<td>2.30 work RVUs</td>
<td>Global $251 Professional $113</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.96 Total NonFacility RVUs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.12 Total Facility RVUs (-26)</td>
<td></td>
</tr>
</tbody>
</table>
## Computed Tomography (CT) — Baseline and Follow-Up

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>RVU</th>
<th>CY 2020 National Average Payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>75572</td>
<td>Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venuous structures, if performed).</td>
<td>1.75 work RVUs 7.01 NonFacility Total RVUs 2.46 Facility Total RVUs (-26)</td>
<td>Global $271 Professional $89</td>
</tr>
<tr>
<td>75574</td>
<td>Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venuous structures, if performed)</td>
<td>2.40 work RVUs 10.13 NonFacility Total RVUs 3.35 Facility Total RVUs (-26)</td>
<td>Global $366 Professional $121</td>
</tr>
</tbody>
</table>

**Commercial payment will vary and will be at discretion of the payer.**

**Global includes professional and technical services. Professional only includes services reported with -26 modifier.**
# Transesophageal Echocardiogram (TEE) — Intraoperative

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>RVU</th>
<th>CY 2020 National Average Payment**</th>
</tr>
</thead>
<tbody>
<tr>
<td>93355</td>
<td>Echocardiography, transesophageal (TEE) for guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (e.g., TAVR, transcatheter pulmonary valve replacement, mitral valve repair, paravalvular regurgitation repair, left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural), real-time image acquisition and documentation, guidance with quantitative measurements, probe manipulation, interpretation, and report, including diagnostic transesophageal echocardiography and, when performed, administration of ultrasound contrast, Doppler, color flow, and 3D.</td>
<td>6.58 Total RVUs</td>
<td>$237</td>
</tr>
</tbody>
</table>

*Commercial payment will vary and will be at discretion of the payer.

**Code 93355 RVU for global payment only, no separate professional component applies.

---

**Same Physician Performing Anesthesia and Intraoperative TEE**

CPT 01926 (Anesthesia) and 93355 (Intraoperative TEE) can not be billed by the physician billing 01926.

PROFESSIONAL CLAIM BILLING INSTRUCTIONS

1. **CPT Code 33340** Percutaneous transcatheter closure of the left atrial appendage with implant, including fluoroscopy transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, radiological supervision and interpretation.

2. **Principal ICD-10-CM Diagnosis Code** (one of the following):
   - I48.0 – Paroxysmal atrial fibrillation
   - I48.11 – Longstanding persistent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.19 – Other persistent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.20 – Chronic atrial fibrillation, unspecified* (NEW Effective October 1, 2019)
   - I48.21 – Permanent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.91 – Unspecified atrial fibrillation

3. **Place of Service Code of 21** – Inpatient hospital

4. **Secondary Diagnosis Code Z00.6** – Encounter for exam of participant in clinical research program to indicate a patient is participating in LAAO Registry

5. **Modifier Q0** – Indicating the procedure is an investigational clinical service provided in an approved clinical research study

6. **Clinical Trial Number** – CT 02699957

---

The 8-digit clinical trial registry number preceded by the alpha characteristic “CT”, is placed in field/item 19 of the CMS 1500 claim form or in the electronic claim equivalent 837p in Loop 2300 REF02(REF01=P4)(this is actually field/item 23).

*The unspecified code is NOT COVERED under the CMS NCD for LAAC. Some private payers have included this ICD-10 code in their coverage policy.*
**CMS 1500 Claim Example for WATCHMAN™ LAAO Device**

**Sources:**
- Items 21A-21B & 24B-24D) CMS Medicare Claims Processing Transmittal 3515; Medlearn Matters Number MM9638 Item 23-1) CMS Medicare Medlearn Matters Number MM9638; Claims Processing Transmittal 2955
- Item 24D) Official AMA CPT code description 33340 Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation.

---

**Item 21A designates the primary diagnosis codes as required by Medicare.**

One of the following diagnosis codes are allowed:
- I48.0-Paroxysmal atrial fibrillation
- I48.11-Longstanding persistent atrial fibrillation
- I48.19-Other persistent atrial fibrillation
- I48.20-Chronic atrial fibrillation, unspecified*
- I48.21-Permanent atrial fibrillation
- I48.91-Unspecified atrial fibrillation

*The unspecified code is NOT COVERED under the CMS NCD for LAAC. Some private payers have included this ICD-10 code in their coverage policy.

**Item 21B designates the secondary ICD-10-CM diagnosis code Z00.6 (Encounter for examination of participant in clinical research program) to indicate the patient is participating in the LAAO registry.**

**Item 23 designates the National Clinical Trial (NCT) number for the Left Atrial Appendage Occlusion (LAAC) registry.**

**Item 24B designates place of service (POS) 21 for inpatient hospital as required by Medicare.**

**Item 24D designates the HCPCS modifier Q0 (Investigational service provided in a clinical research study) to indicate the patient is participating in the LAAO registry.**

---

**Sources:**
- Items 21A-21B & 24B-24D) CMS Medicare Claims Processing Transmittal 3515; Medlearn Matters Number MM9638 Item 23-1) CMS Medicare Medlearn Matters Number MM9638; Claims Processing Transmittal 2955
- Item 24D) Official AMA CPT code description 33340 Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation.
INSTITUTIONAL HOSPITAL CLAIMS BILLING INSTRUCTIONS

1. **ICD-10-PCS Procedure Code 02L73DK** Occlusion of Left Atrial Appendage with Intraluminal Device, Percutaneous Approach

2. **Principal ICD-10-CM Diagnosis Code** of one of the following:
   - I48.0 – Paroxysmal atrial fibrillation
   - I48.11 – Longstanding persistent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.19 – Other persistent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.20 – Chronic atrial fibrillation, unspecified* (NEW Effective October 1, 2019)
   - I48.21 – Permanent atrial fibrillation (NEW Effective October 1, 2019)
   - I48.91 – Unspecified atrial fibrillation

3. **Secondary Diagnosis Code Z00.6** – Encounter for exam of participant in clinical research program to indicate a patient is participating in LAAO Registry

4. **Condition Code 30** – Qualifying Clinical Trial

5. **Value Code D4** – Clinical Trial Number (NCT 02699957) is listed on the CMS website: clinicaltrials.gov

*The unspecified code is **NOT COVERED** under the CMS NCD for LAAC. Some private payers have included this ICD-10-CM code in their coverage policy.


**CMS Inpatient UB-04 Claim Example for WATCHMAN™ LAAO Device**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Designates the condition code which indicates a qualifying clinical trial.</td>
</tr>
<tr>
<td>39</td>
<td>Designates the value code and National Clinical Trial (NCT) number for the Left Atrial Appendage Occlusion (LAAO) registry.</td>
</tr>
<tr>
<td>66/67</td>
<td>Designates the primary diagnosis codes as required by Medicare. One of the following diagnosis codes is allowed: I48.0-Paroxysmal atrial fibrillation, I48.11-Longstanding persistent atrial fibrillation, I48.19-Other persistent atrial fibrillation, I48.20-Chronic atrial fibrillation, unspecified, I48.21-Permanent atrial fibrillation, I48.91-Unspecified atrial fibrillation.</td>
</tr>
<tr>
<td>67A</td>
<td>Designates the secondary ICD-10-CM diagnosis code Z00.6 (Encounter for examination of participant in clinical research program) to indicate the patient is participating in the LAAO registry.</td>
</tr>
<tr>
<td>67</td>
<td>Designates the secondary ICD-10-CM diagnosis code Z00.6 (Encounter for examination of participant in clinical research program) to indicate the patient is participating in the LAAO registry.</td>
</tr>
<tr>
<td>74</td>
<td>Designates the principal ICD-10 PCS code. Code 02L73DK (Occlusion of Left Atrial Appendage with Intraluminal Device, Percutaneous Approach) represents the designated code for the WATCHMAN™ device.</td>
</tr>
</tbody>
</table>

Sources:

IC-471408-AA MAY2017
Device C-Code

The WATCHMAN device is classified by Medicare as an “Inpatient Only” procedure therefore no HCPCS device category C-code exists for WATCHMAN

- A hospital may assign its own internal charge code, associated with an appropriate revenue code, to record the cost of the device.

- If a device category C-code is required by the hospital charging system, please review the web link below for the CMS approved list as of January 1, 2019.

Using the camera on your phone, scan the QR code and visit the sites.

https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/Complet-list-DeviceCats-OPPS.pdf
DISCONTINUED OR ABORTED PROCEDURE FOR IN-PATIENT SERVICES

Discontinued or Aborted Procedures vary based on patient case details and physician documentation. The following scenario represents only one type of case. Consult AHA Coding Clinic and Official Coding Guidelines in the event of other clinical scenarios.

Scenario: During same operative episode the WATCHMAN device was inserted, determined by the physician to be inadequate and the device was removed.

ICD-10 PCS 02H73DZ Insertion of Intraluminal Device into Left Atrium, Percutaneous Approach
• Root Operation Definition: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part.

AND

ICD-10 PCS 02PA3DZ Removal of Intraluminal Device from Heart, Percutaneous Approach
• Root Operation Definition: Taking out or off a device from a body part.

2020 ICD-10 PCS Official Guidelines for Coding and Reporting (page 76), Guideline B6.1a.
DISCONTINUED OR ABORTED PHYSICIAN SERVICES

- CPT Code 33340
- May use modifier 53 for a Discontinued Procedure
- The modifier is used to report services or procedures when the service/procedure is discontinued after anesthesia is administered to the patient. Submit the length/amount of procedure completed and reason for discontinued services.
- The physician can only code for what was accomplished in the procedure (e.g., groin access; or, transseptal puncture and imaging; or, inspection, insertion and removal)

2019 ICD-10 PCS Official Guidelines for Coding and Reporting (page 76), Guideline B6.1a.
American Hospital Association (AHA) Coding Clinic for ICD-10-CM/PCS, Fourth Quarter 2017: Page 104;
Fourth Quarter ICD-10 2018 Page: 94
CONCOMITANT PROCEDURE BILLING FOR HOSPITAL INPATIENT SERVICES

MS-DRG Hierarchy

When a WATCHMAN device is performed during the same hospital admission as another procedure, only one MS-DRG is assigned for payment.

- Since a patient can have multiple procedures related to their principal diagnosis, and a patient can be assigned to only MS-DRG, patients with multiple procedures are assigned to the surgical class highest in the CMS defined hierarchy.
- Each case is specific to clinical circumstances of the admission.
- The assignment of the principal diagnosis and procedure are critical for accurate MS-DRG assignment.
- Sequence procedure performed for definitive treatment most related to principal diagnosis as principal procedure.

Inpatient Readmissions

When an inpatient hospital WATCHMAN device admission follows a previous inpatient admission for a related or unrelated procedure, readmission policies may apply. A quality review may be triggered and warrant a case review to evaluate combining the inpatient admissions. Each case is specific to clinical circumstances for each admission.


CONCOMITANT PROCEDURE BILLING FOR PHYSICIAN SERVICES

When a WATCHMAN device is performed during the same operative episode as another procedure, the Medicare Multiple Discounting policy applies.

- **Multiple Procedure Discount** – payment adjustment rule for multiple procedures applies to the service. The WATCHMAN procedure is assigned a ‘2’ which indicates that standard payment adjustment rules for multiple procedures apply.
  
  - 100 percent of the fee schedule amount for the highest valued procedure; and
  
  - 50 percent of the fee schedule amount for the second through the fifth highest valued procedures

When a WATCHMAN device is performed on a separate date of service as another procedure, the Medicare Global Days policy applies.

- **Global Days** – time frames that apply to payment for each surgical procedure that describes the applicability of the global concept to the service.

  - WATCHMAN is assigned a 000 global surgery payment indicator. Therefore, only the preoperative and postoperative services related to the procedure for the day of surgery apply. Any services after the day of surgery are separately billable.

NATIONAL COVERAGE DETERMINATION (NCD 20.34)

CMS issued the final decision memo that supports a National Coverage Determination (NCD) for Medicare beneficiaries undergoing Percutaneous Left Atrial Appendage (LAAC) Closure Therapy.

NCD 20.34 outlines specific criteria for WATCHMAN eligibility.

Decision Memo for Percutaneous Left Atrial Appendage (LAA) Closure Therapy:

Using the camera on your phone, scan the QR code and visit the sites.


The criteria are highlighted below. Providers are encouraged to read the decision memo in its entirety for additional detail.

The patient must have:

- A CHADS\textsubscript{2} score $\geq 2$ (Congestive heart failure, Hypertension, Age $>75$, Diabetes, Stroke/transient ischemia attack/thromboembolism) or CHA\textsubscript{2}DS\textsubscript{2}-VASc score $\geq 3$ (Congestive heart failure, Hypertension, Age $\geq 65$, Diabetes, Stroke/transient ischemia attack/thromboembolism, Vascular disease, Sex category)

- A formal shared decision-making interaction with an independent non-interventional physician using an evidence-based decision tool on oral anticoagulation in patients with NVAF prior to LAAC. Additionally, the shared decision-making interaction must be documented in the medical record.
**NATIONAL COVERAGE DETERMINATION (NCD 20.34)**

Continued

**Shared Decision Making Resources**

Using the camera on your phone, scan the QR code and visit the sites.

- [American College of Physicians](https://www.acponline.org/patients_families/products/brochures/afib_booklet.pdf)
- [National Institute for Health and Care Excellence](https://www.nice.org.uk/guidance/cg180/resources/patient-decision-aid-243734797)
- [CardioSmart](http://www.acc.org/tools-and-practice-support/quality-programs/anticoagulation-initiative/anticoagulation-shared-decision-making-tool)

- A suitability for short-term warfarin but deemed unable to take long term oral anticoagulation following the conclusion of shared decision making
- The patient (preoperatively and postoperatively) is under the care of a cohesive, multidisciplinary team (MDT) of medical professionals
- The procedure must be furnished in a hospital with an established structural heart disease (SHD) and/or electrophysiology (EP) program
• The procedure must be performed by an interventional cardiologist(s), electrophysiologist(s) or cardiovascular surgeon(s) that meet the following criteria:

– Has received training prescribed by the manufacturer on the safe and effective use of the device prior to performing LAAC; and

– Has performed $\geq 25$ interventional cardiac procedures that involve transseptal puncture through an intact septum; and

– Continues to perform $\geq 25$ interventional cardiac procedures that involve transseptal puncture through an intact septum, of which at least 12 are LAAC, over a two-year period.

• The patient is enrolled in, and the MDT and hospital must participate in a prospective, national, audited registry that:

1) consecutively enrolls LAAC patients and

2) tracks the annual outcomes for each patient for a period of at least four years from the time of the LAAC

**LAAO REGISTRY™**

CMS has certified the LAAO Registry (NCT02699957) as the national registry for data collection for LAAC procedures. The long-term data collection supports CMS’s coverage with evidence development (CED) to ensure better visibility of safety and effectiveness of LAAC procedures.

Hospitals performing WATCHMAN must contact the National Cardiovascular Data Registry (NCDR®) at ncdr@acc.org or 1-800-257-4737 to enroll in the LAAO Registry™.

Using the camera on your phone, scan the QR code and visit the sites.

**MEDICARE ADVANTAGE**

Medicare Advantage health plans are administered by Medicare Advantage Organizations (MAO). MAO plans are required to offer the same coverage as Original Medicare, however MAOs conduct a medical necessity review through Utilization Management (UM). The review for medical necessity may take up to two weeks. The MAO is required to communicate their decision to the provider and patient in writing.

**MEDICAID**

Medicaid plans vary with respect to their coverage of the WATCHMAN LAAC Therapy. You may contact the Boston Scientific Reimbursement Support Line for information regarding state-specific coverage status.

Please contact:

WATCHMAN.Reimbursement@bsci.com or 877-786-1050
Patients often obtain health insurance from their employer, or purchase through an exchange. Commercial health insurance contractually requires prior authorization before services are rendered. The Commercial Health Insurance reviews applicable data and reviews for medical necessity. Their determination is communicated to the provider and patient in writing. This process can take up to two weeks.

Commercial payers may choose to follow the NCD or establish their own policies for LAAC therapy. It is important to review individual coverage policies and to seek prior authorization to establish medical necessity for WATCHMAN in advance of performing the procedure.

Please refer to the WATCHMAN Download Center for the most up-to-date list of WATCHMAN private payer coverage and for resources to support prior authorization and appeals.

Using the camera on your phone, scan the QR code and visit the sites.

https://www.watchman.com/hcp/watchman-download-center/health-economics-and-reimbursement.html

The Boston Scientific Prior Authorization Team provides assistance in submitting prior authorization requests. Boston Scientific also provides support with appealing denials. The release of patient information is required.

Phone: (877) 786-1050. Press 1 to connect with WATCHMAN Prior Authorization or Appeals support.

Submit completed Boston Scientific prior authorization forms and associated materials to:

Email: PreAuthSupport@bsci.com

Fax: 877-835-2520
### COMMERCIAL HEALTH INSURANCE

**WATCHMAN Private Payer Coverage (March 2020)**

<table>
<thead>
<tr>
<th>Health Plan</th>
<th>Primary Service Area</th>
<th>Health Plan</th>
<th>Primary Service Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>AETNA</td>
<td>National</td>
<td>BCBS of Federal Employee Program</td>
<td>National</td>
</tr>
<tr>
<td>AmeriHealth</td>
<td>PA, NJ, DC</td>
<td>BCBS of Wyoming</td>
<td>WY</td>
</tr>
<tr>
<td>Arkansas Health</td>
<td>AR</td>
<td>Blue Cross ID</td>
<td>ID</td>
</tr>
<tr>
<td>Avera</td>
<td>FL, SD, IA, NB</td>
<td>Blue Shield CA</td>
<td>CA</td>
</tr>
<tr>
<td>AvMed</td>
<td>FL</td>
<td>Capital Health Plan</td>
<td>FL</td>
</tr>
<tr>
<td>BCBS of AL</td>
<td>AL</td>
<td>Capital Bluecross</td>
<td>PA</td>
</tr>
<tr>
<td>BCBS of AR</td>
<td>AR</td>
<td>CareFirst BCBS</td>
<td>DC, MD, VA</td>
</tr>
<tr>
<td>BCBS Health Advantage</td>
<td>TX</td>
<td>CareSource</td>
<td>OH</td>
</tr>
<tr>
<td>BCBS of AZ</td>
<td>AZ</td>
<td>Centene</td>
<td>National</td>
</tr>
<tr>
<td>BCBS of FL</td>
<td>FL</td>
<td>Health Net Federal Services</td>
<td>National</td>
</tr>
<tr>
<td>BCBS of IL</td>
<td>IL</td>
<td>Arizona Complete Health</td>
<td>AZ</td>
</tr>
<tr>
<td>BCBS of Kansas</td>
<td>KS</td>
<td>Bridgeway Health Solutions</td>
<td>AZ</td>
</tr>
<tr>
<td>BCBS of Kansas City</td>
<td>KS</td>
<td>Health Net (CA)</td>
<td>CA</td>
</tr>
<tr>
<td>BCBS of Louisiana</td>
<td>LA</td>
<td>California Health and Wellness</td>
<td>CA</td>
</tr>
<tr>
<td>BCBS of MA</td>
<td>MA, RI</td>
<td>Sunshine Health</td>
<td>FL</td>
</tr>
<tr>
<td>BCBS of MI</td>
<td>MI</td>
<td>Peach State Health</td>
<td>GA</td>
</tr>
<tr>
<td>BCBS of MS</td>
<td>MS</td>
<td>Celtic (IL)</td>
<td>IL</td>
</tr>
<tr>
<td>BCBS of MT</td>
<td>MT</td>
<td>IlliniCare Health</td>
<td>IL</td>
</tr>
<tr>
<td>BCBS of NC</td>
<td>NC</td>
<td>Managed Health Services (IN)</td>
<td>IN</td>
</tr>
<tr>
<td>BCBS of NM</td>
<td>NM</td>
<td>Sunflower State Health</td>
<td>KS</td>
</tr>
<tr>
<td>BCBS Western NY</td>
<td>NY</td>
<td>Louisiana HealthCare Connections</td>
<td>LA</td>
</tr>
<tr>
<td>BCBS of OK</td>
<td>OK</td>
<td>CeltiCare Health</td>
<td>MA</td>
</tr>
<tr>
<td>BCBS of RI</td>
<td>RI</td>
<td>Michigan Complete Health</td>
<td>MI</td>
</tr>
<tr>
<td>BCBS of TN</td>
<td>TN</td>
<td>Home State Health</td>
<td>MO</td>
</tr>
<tr>
<td>BCBS of TX</td>
<td>TX</td>
<td>Magnolia Health</td>
<td>MS</td>
</tr>
<tr>
<td>BCBS of SC</td>
<td>SC</td>
<td>Nebraska Total Care</td>
<td>NE</td>
</tr>
<tr>
<td>BCBS of Wyoming</td>
<td>WY</td>
<td>New Hampshire Healthy Families</td>
<td>NH</td>
</tr>
</tbody>
</table>
### COMMERCIAL HEALTH INSURANCE

**Continued**

<table>
<thead>
<tr>
<th>Health Plan</th>
<th>Primary Service Area</th>
<th>Health Plan</th>
<th>Primary Service Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>SilverSummit</td>
<td>NV</td>
<td>Horizon BCBS</td>
<td>NJ</td>
</tr>
<tr>
<td>Buckeye Health</td>
<td>OH</td>
<td>Humana</td>
<td>National</td>
</tr>
<tr>
<td>Trillium Community Health</td>
<td>OR</td>
<td>Independence Blue Cross</td>
<td>PA</td>
</tr>
<tr>
<td>Health Net (OR)</td>
<td>OR</td>
<td>Kaiser Permanente</td>
<td>National</td>
</tr>
<tr>
<td>Pennsylvania Health &amp; Wellness</td>
<td>PA</td>
<td>LifeWise</td>
<td>OR, WA</td>
</tr>
<tr>
<td>Absolute Total Care</td>
<td>SC</td>
<td>Medical Mutual of Ohio</td>
<td>OH</td>
</tr>
<tr>
<td>Superior HealthPlan</td>
<td>TX</td>
<td>Nebraska Blue</td>
<td>NE</td>
</tr>
<tr>
<td>Coordinated Care</td>
<td>WA</td>
<td>Optima (Sentara)</td>
<td>VA, OH, NC, WV, Fl, MD, PA, SC, GA, CA</td>
</tr>
<tr>
<td>Managed Health Services (WI)</td>
<td>WI</td>
<td>Paramount Healthcare</td>
<td>OH, MI</td>
</tr>
<tr>
<td>Coordinated Care Health Plan</td>
<td>WA</td>
<td>Premera Blue Cross</td>
<td>WA, AK, OR</td>
</tr>
<tr>
<td>Dean Health Plan</td>
<td>WI</td>
<td>Prevera 360</td>
<td>WI</td>
</tr>
<tr>
<td>Emblem Health</td>
<td>NY, CT, NJ, Fl, PA, NC, MA, SC, GA, CA</td>
<td>Priority Health</td>
<td>MI</td>
</tr>
<tr>
<td>Excellus</td>
<td>NY, CT</td>
<td>Regence Health Plan</td>
<td>IA, OH, UT, WA</td>
</tr>
<tr>
<td>Fallon</td>
<td>MA, NY, CT, Fl, PA, SC</td>
<td>Scott &amp; White Health Plan</td>
<td>TX</td>
</tr>
<tr>
<td>Group Health</td>
<td>WA</td>
<td>Summa Health</td>
<td>OH, MD</td>
</tr>
<tr>
<td>Harvard Pilgrim</td>
<td>MA, ME, CT, NH, RI, VT, NY</td>
<td>TriCare</td>
<td>National</td>
</tr>
<tr>
<td>Hawaii Medical Services Association (HMSA)</td>
<td>HI</td>
<td>Tufts Health Plan</td>
<td>MA, RI, NY</td>
</tr>
<tr>
<td>Health Alliance of MI</td>
<td>MI</td>
<td>UPMC</td>
<td>PA</td>
</tr>
<tr>
<td>HealthNow (BCBSWNY, BCBSNENY)</td>
<td>NY</td>
<td>Univera</td>
<td>NY</td>
</tr>
<tr>
<td>Health New England</td>
<td>MA, CT</td>
<td>Wellmark Blue Cross Blue Shield</td>
<td>IA, SD</td>
</tr>
<tr>
<td>Highmark BCBS</td>
<td>DE, PA, WV</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Covered lives for Commercial and Federal plans is based on estimates available from Policy Reporter, and excludes those covered by Medicare Advantage plans and/or Medicaid.
ADDITIONAL RESOURCES FOR HEALTH ECONOMICS & MARKET ACCESS SUPPORT

Boston Scientific’s Health Economics and Market Access Team is pleased to offer a series of educational webinars to support customers in areas of coding, coverage and market access for their WATCHMAN programs. Please use the following website to register for upcoming webinars:


Using the camera on your phone, scan the QR code and visit the sites.

The webinar topics listed below will be covered each Tuesday on a monthly basis through December 2020:

**First Tuesday: Coding and Claims for WATCHMAN procedure**
12:00-1:00 pm EST and 3:00-4:00 pm EST
- Understanding WATCHMAN assigned DRGs
- Importance of Documentation
- Review of claims processing for institution and physician

**Second Tuesday: National Coverage Determination**
12:00-1:00 pm EST and 3:00-4:00 pm EST
- Patient eligibility criteria and shared decision-making
- Facility and Operator Requirements
- National LAAC Registry

**Third Tuesday: Resources Supporting Prior Authorization, Appeals and Beyond**
12:00-1:00 pm EST and 3:00-4:00 pm EST
- Best practices and tools
- Review of Boston Scientific resources
- Commercial payor landscape for Watchman coverage

Any questions regarding these webinars can be directed to ICHEMATEAM@BSCI.COM